South Korea's Financial Supervisory Service (FSS) Dispute Mediation Committee ruled on May 24 that follow-up observations without treatment prior to joining simplified underwriting insurance do not constitute disclosure obligations. The committee adjudicated two cases involving simplified insurance products designed for chronic disease patients with conditions such as hypertension and diabetes. The rulings clarified that routine monitoring recommended by physicians falls outside mandatory pre-contract disclosure requirements, and established that hospitalizations for clinical trial participation do not qualify as 'hospitalization due to disease' under policy terms.
FSS Rules Follow-Up Observation Not Disclosure Obligation in Case A
Applicant A joined simplified underwriting insurance in April 2023 and was diagnosed with myelodysplastic syndrome in July 2024. The applicant filed a claim for specific cancer diagnosis benefits with the insurer. In March 2023, three months before joining the insurance, the applicant received a physician's recommendation for a blood test two months later. The insurer terminated the contract and denied payment, citing failure to disclose this recommendation as a violation of the obligation to report 'additional test recommendations within three months' before contract signing.
The FSS Dispute Mediation Committee interpreted 'additional test' according to legal precedent as examinations required for more accurate diagnosis following initial test results. The FSS previously clarified that regular checkups or follow-up observations conducted without treatment necessity are excluded from this definition. The committee determined the blood test recommendation constituted follow-up observation rather than additional testing, as no abnormalities were detected and the recommendation aimed solely at monitoring platelet levels. The committee ordered the insurer to pay the insurance benefits.
Committee Excludes Clinical Trial Hospitalization from Disease Hospitalization in Case B
Applicant B joined simplified underwriting insurance in March 2022 and was hospitalized due to disease in January-February 2024. The applicant filed a claim for daily caregiver benefits during disease hospitalization. The applicant participated in clinical trials testing new drug efficacy in December 2019 and April 2021, with four-day hospitalizations for each trial. The insurer terminated the contract and denied payment, citing failure to disclose these hospitalizations as violations of the obligation to report 'hospitalization due to disease within three years' before contract signing.
The committee interpreted 'hospitalization due to disease' based on court rulings as cases where disease symptoms necessitate conventional inpatient treatment or management requiring hospital stays. The committee determined clinical trial hospitalizations do not constitute hospitalization due to disease. Hospital admission records listed clinical trial participation as the purpose, and individual treatment acts could not be established under clinical trial protocols. The committee ordered the insurer to pay the insurance benefits.
FSS Commits to Consumer Protection Through Active Mediation
The FSS stated it will guide insurers toward establishing prompt and reasonable insurance payment practices for simplified underwriting insurance. The agency announced plans to continue financial consumer protection efforts by actively convening dispute mediation committees.
FAQ
What did South Korea's FSS rule on May 24 regarding simplified insurance disclosure?
The FSS Dispute Mediation Committee ruled that follow-up observations without treatment prior to joining simplified underwriting insurance do not constitute mandatory disclosure obligations, and that hospitalizations for clinical trial participation do not qualify as 'hospitalization due to disease' under policy terms.
Why did the FSS committee order insurers to pay benefits in both cases?
In Case A, the committee determined a blood test recommendation for routine platelet monitoring constituted follow-up observation rather than additional testing requiring disclosure. In Case B, the committee ruled clinical trial hospitalizations did not meet the definition of disease hospitalization because they lacked conventional treatment necessity and served research purposes documented in admission records.
